Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
01 Cellular Research Combines BPC-157, TB-500, GHK-Cu, and KPV for multi-pathway tissue repair and recovery research in a single vial
These combinations lack clinical validation and require careful monitoring for adverse interactions
Smoking People with lupus who smoke tend to have more active disease and discoid lupus involvement, which causes round disc-shaped sores and can lead to scarring
We're discussing how we will improve access to care for active military and veterans, and why we feel it is important
Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%
US$ 25.00
US$ 24.49
US$ 23.46
US$ 20.31
US$ 20.71
US$ 26.92
